Citation

Sanchez C, Keri J. Clin. Cosmet. Investig. Dermatol. 2022; 15: 1357-1366.

Copyright

(Copyright © 2022, Dove Medical Press)

DOI

10.2147/CCID.S289750

PMID

unavailable

Abstract

The purpose of this narrative review is to provide a summary of the clinical trials on the efficacy and safety of clascoterone 1% cream (Winlevi) to grant providers an understanding of which patients will benefit most from this novel topical antiandrogen medication. Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris. This topical androgen antagonist is the first of its kind but will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy. © 2022 Sanchez and Keri.

Language: en

Keywords

human; Review; suicide attempt; treatment outcome; inflammation; acne vulgaris; headache; drug structure; nonhuman; drug safety; drug efficacy; drug tolerability; patient satisfaction; erythema; side effect; hypothalamus hypophysis adrenal system; contact dermatitis; experimental study; rhinopharyngitis; hyperplasia; cream; oropharynx pain; clascoterone; anti-androgens; application site dryness; application site swelling; CB-03-01; depigmentation; hormonal acne; injection site hypersensitivity; Winlevi